Jefferies Financial Group Inc. Buys 200,000 Shares of Compass Pathways PLC Sponsored ADR $CMPS

Jefferies Financial Group Inc. raised its stake in Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) by 14.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,576,905 shares of the company’s stock after buying an additional 200,000 shares during the period. Jefferies Financial Group Inc. owned about 1.64% of Compass Pathways worth $10,881,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in CMPS. Nantahala Capital Management LLC increased its holdings in shares of Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares during the last quarter. Ameriprise Financial Inc. bought a new position in shares of Compass Pathways in the 3rd quarter worth $6,926,000. Two Sigma Investments LP increased its holdings in shares of Compass Pathways by 838.4% in the 3rd quarter. Two Sigma Investments LP now owns 1,075,277 shares of the company’s stock worth $6,161,000 after buying an additional 960,685 shares during the last quarter. Eagle Health Investments LP bought a new position in shares of Compass Pathways in the 3rd quarter worth $5,360,000. Finally, Millennium Management LLC increased its holdings in shares of Compass Pathways by 39.9% in the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after buying an additional 774,090 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

Compass Pathways Price Performance

CMPS stock opened at $11.81 on Monday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.32 and a current ratio of 3.32. Compass Pathways PLC Sponsored ADR has a 52 week low of $2.25 and a 52 week high of $12.24. The firm’s fifty day moving average is $7.63 and its 200 day moving average is $6.91. The firm has a market cap of $1.59 billion, a P/E ratio of -3.75 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last released its earnings results on Wednesday, May 13th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.15. Research analysts predict that Compass Pathways PLC Sponsored ADR will post -1.24 earnings per share for the current year.

Analysts Set New Price Targets

CMPS has been the topic of a number of research analyst reports. Canaccord Genuity Group decreased their price target on shares of Compass Pathways from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, March 26th. UBS Group set a $18.00 price target on shares of Compass Pathways in a report on Thursday, May 7th. Lifesci Capital raised shares of Compass Pathways to a “strong-buy” rating in a report on Thursday, February 12th. Wolfe Research initiated coverage on shares of Compass Pathways in a report on Friday. They issued an “outperform” rating on the stock. Finally, B. Riley Financial initiated coverage on shares of Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $20.58.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.